Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  11:31:51 2023-01-26 am EST
82.68 CHF   -3.07%
01/25Novartis Files Petition With Supreme Court to Protect Gilenya Patent
MT
01/25NOVARTIS AG : Sell rating from Barclays
MD
01/25Deciphex Limited announced that it has received €14.8 million in funding from a group of investors
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis : manufactures and donates 27,000 units of hand sanitizer to New York State

06/16/2020 | 08:06am EST

Long Island, New York - Novartis, through its Long Island Operations site known as Fougera, today announces the donation of 27,000 units of hand sanitizer to support New York's response to the COVID-19 public health emergency. As part of the larger Novartis COVID-19 Community Response Fund, the Novartis US Foundation has established a Fund and mechanism to support local efforts such as this.

Long Island Operations began manufacturing hand sanitizer at the Hicksville site to help with the pandemic as well as for internal Novartis use in the U.S. The hand sanitizer donation will support statewide first responders including hospitals, state agencies, nursing homes, nonprofit organizations and others.

'It is the first time we have manufactured hand sanitizer. With the hard work and dedication of all of the associates, we quickly put all of the pieces in place to make this happen,' said James Apollo, Director Operations, Site Head. 'Our associates are the heroes, and I am exceptionally proud of the work that was done. They remain engaged and dedicated to support not just our patients, customers, co-workers, and company, but also the community where we work and live.'

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such 'potential,' 'can,' 'will,' 'plan,' 'expect,' 'anticipate,' 'look forward,' 'move forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products, or regarding the transaction described in this press release. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that our US generic oral solids and dermatology businesses will be successful in the future. Neither can there be any guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that, if approved, such products will be approved for all indications included in the reference product's label, or commercially successful in the future. In particular, our expectations regarding such businesses and products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Located in East Hanover, NJ Novartis Pharmaceuticals Corporation - an affiliate of Novartis - is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis employs about 15,000 people in the United States. For more information, please visit http://www.novartis.us.

Novartis and Novartis US is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartisnews and @NovartisUS at https://twitter.com/NovartisUS

For Novartis multimedia content, please visit www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

Novartis Media Relations

E-mail: media.relations@novartis.com

Eric Althoff

Head, US Corp & Country External Comms

Global Media & Corp Communications

+1 646 438 4335

eric.althoff@novartis.com

Chris Lewis

Sandoz Global Communications

+49 174 244 9501 (mobile)

chris.lewis@sandoz.com

Jamie Bennett

Director, US Media Relations

+1 862-217-3976

jamie.bennett@novartis.com

Leslie Pott

Sandoz US Communications

+1 201 354 0279 (mobile)

leslie.pott@sandoz.com

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about NOVARTIS AG
01/25Novartis Files Petition With Supreme Court to Protect Gilenya Patent
MT
01/25NOVARTIS AG : Sell rating from Barclays
MD
01/25Deciphex Limited announced that it has received €14.8 million in funding from a gr..
CI
01/24Global markets live: GE, J&J, Verizon, Lockheed Martin, Halliburton...
MS
01/24Europe's revenue growth expected to slow to a crawl in Q4
RE
01/24Sandoz announces agreement to acquire leading antifungal agent Mycamine from Astellas, ..
AQ
01/24NOVARTIS AG : Goldman Sachs reiterates its Buy rating
MD
01/23Novartis' Sandoz to Buy Global Rights for Antifungal Medicine Mycamine
MT
01/23Sandoz announces agreement to acquire leading antifungal agent Mycamine« from Astellas,..
GL
01/23Novartis : Sandoz announces agreement to acquire leading antifungal agent Mycam..
DJ
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2022 51 305 M - -
Net income 2022 8 589 M - -
Net Debt 2022 7 406 M - -
P/E ratio 2022 22,1x
Yield 2022 3,72%
Capitalization 193 B 193 B -
EV / Sales 2022 3,91x
EV / Sales 2023 3,87x
Nbr of Employees 108 000
Free-Float 87,1%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Last Close Price 89,72 $
Average target price 95,60 $
Spread / Average Target 6,56%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG2.05%199 399
JOHNSON & JOHNSON-4.04%443 181
ELI LILLY AND COMPANY-4.40%332 306
NOVO NORDISK A/S1.07%313 303
ROCHE HOLDING AG1.07%281 267
MERCK & CO., INC.-3.68%275 319